Rallybio Corporation (RLYB)

Rallybio Statistics

Total Valuation

Rallybio has a market cap or net worth of $84.00 million. The enterprise value is $37.36 million.

Market Cap	84.00M
Enterprise Value	37.36M

Important Dates

The last earnings date was Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Rallybio has 5.29 million shares outstanding. The number of shares has increased by 1.50% in one year.

Current Share Class	5.29M
Shares Outstanding	5.29M
Shares Change (YoY)	+1.50%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	4.16%
Owned by Institutions (%)	34.10%
Float	2.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	97.90
Forward PS	n/a
PB Ratio	1.67
P/TBV Ratio	1.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	43.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.92, with a Debt / Equity ratio of 0.00.

Current Ratio	12.92
Quick Ratio	11.30
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -14.98% and return on invested capital (ROIC) is -36.35%.

Return on Equity (ROE)	-14.98%
Return on Assets (ROA)	-33.82%
Return on Invested Capital (ROIC)	-36.35%
Return on Capital Employed (ROCE)	-60.45%
Weighted Average Cost of Capital (WACC)	-1.80%
Revenue Per Employee	$61,286
Profits Per Employee	-$558,357
Employee Count	14
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +509.36% in the last 52 weeks. The beta is -1.10, so Rallybio's price volatility has been lower than the market average.

Beta (5Y)	-1.10
52-Week Price Change	+509.36%
50-Day Moving Average	10.39
200-Day Moving Average	6.62
Relative Strength Index (RSI)	84.14
Average Volume (20 Days)	647,898

Short Selling Information

The latest short interest is 1.57 million, so 29.74% of the outstanding shares have been sold short.

Short Interest	1.57M
Short Previous Month	1.41M
Short % of Shares Out	29.74%
Short % of Float	75.85%
Short Ratio (days to cover)	23.93

Income Statement

In the last 12 months, Rallybio had revenue of $858,000 and -$7.82 million in losses. Loss per share was -$1.38.

Revenue	858,000
Gross Profit	-17.54M
Operating Income	-30.43M
Pretax Income	-7.82M
Net Income	-7.82M
EBITDA	-30.36M
EBIT	-30.43M
Loss Per Share	-$1.38

Balance Sheet

The company has $46.80 million in cash and $154,000 in debt, with a net cash position of $46.64 million or $8.82 per share.

Cash & Cash Equivalents	46.80M
Total Debt	154,000
Net Cash	46.64M
Net Cash Per Share	$8.82
Equity (Book Value)	50.28M
Book Value Per Share	9.50
Working Capital	49.35M

Cash Flow

Operating Cash Flow	-27.59M
Capital Expenditures	n/a
Depreciation & Amortization	67,000
Net Borrowing	n/a
Free Cash Flow	-27.59M
FCF Per Share	-$5.22

Margins

Gross Margin	n/a
Operating Margin	-3,546.27%
Pretax Margin	-911.07%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rallybio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.50%
Shareholder Yield	-1.50%
Earnings Yield	-9.31%
FCF Yield	-32.84%

Analyst Forecast

The average price target for Rallybio is $8.00, which is -49.62% lower than the current price. The consensus rating is "Hold".

Price Target	$8.00
Price Target Difference	-49.62%
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	220.74%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 6, 2026. It was a reverse split with a ratio of 1:8.

Last Split Date	Feb 6, 2026
Split Type	Reverse
Split Ratio	1:8

Scores

Altman Z-Score	n/a
Piotroski F-Score	2